Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ozekibart by Inhibrx for Solid Tumor: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Ozekibart by Inhibrx for Metastatic Colorectal Cancer: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ozekibart by Inhibrx for Gastric Cancer: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
Ozekibart by Inhibrx for Sarcomas: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
Ozekibart by Inhibrx for Ewing Sarcoma: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase I...
Ozekibart by Inhibrx for Malignant Pleural Mesothelioma: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase...
Ozekibart by Inhibrx for Synovial Sarcoma: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Synovial Sarcoma. According to GlobalData, Phase I...
Ozekibart by Inhibrx for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Ozekibart is under clinical development by Inhibrx and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to...